Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection
Antiviral therapy in hepatitis C virus (HCV) infection is limited by haematological side-effects, especially thrombocytopenia and leucopenia. The pancytopenia associated with liver cirrhosis has multifactorial causes, but hypersplenism seems to be a major contributor, especially regarding thrombocytopenia. The use of PSE as a 'Pretreatment' in order to make more patients with HCV-induced cirrhosis
